Yan P, Saraga E P, Bouzourene H, Bosman F T, Benhattar J
Institute of Pathology, Centre Hospitalier Universitaire Vaudois, CH-1011 Lausanne, Switzerland.
J Pathol. 1999 Oct;189(2):207-12. doi: 10.1002/(SICI)1096-9896(199910)189:2<207::AID-PATH424>3.0.CO;2-H.
Telomerase activity has been detected in germ cells as well as in the developing embryo. Activity is no longer detectable in most somatic cells of the neonate, although low levels of activity persist in regenerative tissues. Telomerase has been found to be reactivated or up-regulated in the majority of cancers. The colorectal adenoma-carcinoma sequence is one of the best-characterized models of multistep tumourigenesis and is thus suitable for determining at which stage telomerase is activated. Telomerase activity was examined by telomeric repeat amplification protocol (TRAP) assay in 96 cases of colorectal tissues, including 50 carcinomas, 31 adenomas, and 15 normal colonic tissues. For each case, histological diagnosis and telomerase activity were determined on consecutive frozen sections. In order to reduce the chance of a false-negative TRAP assay due to RNA degradation, the integrity of rRNA in the tissues was verified in each case. Twenty-five carcinomas, 30 adenomas, and all of the 15 normal colorectal mucosal samples showed no or only partial rRNA degradation and only in these cases was the TRAP assay interpreted. None of the normal tissues exhibited telomerase activity. In contrast, all of the 25 cancers and 47 per cent (14/30) of the adenomas were positive. In adenomas, telomerase activation was highly significantly related to the grade of dysplasia (p< 0.0001). All adenomas which contained high-grade dysplasia revealed telomerase activity, whereas telomerase activity was detectable in only 20 per cent (4/20) of cases with exclusively low-grade dysplasia. These results indicate that telomerase activation, which may be an obligatory step in colorectal carcinogenesis, occurs in the progression from low-grade to high-grade dysplasia in adenomas. Furthermore, in the adenoma-carcinoma sequence, telomerase activation seems to occur later than K- ras mutation but earlier than p53 mutation.
在生殖细胞以及发育中的胚胎中已检测到端粒酶活性。新生儿的大多数体细胞中不再能检测到该活性,尽管在再生组织中仍存在低水平的活性。已发现端粒酶在大多数癌症中被重新激活或上调。结直肠腺瘤-癌序列是多步骤肿瘤发生的最具特征的模型之一,因此适合确定端粒酶在哪个阶段被激活。通过端粒重复序列扩增协议(TRAP)分析检测了96例结直肠组织中的端粒酶活性,包括50例癌、31例腺瘤和15例正常结肠组织。对于每个病例,在连续的冰冻切片上确定组织学诊断和端粒酶活性。为了减少由于RNA降解导致TRAP分析假阴性的可能性,在每个病例中都验证了组织中rRNA的完整性。25例癌、30例腺瘤和所有15例正常结直肠黏膜样本均未显示或仅部分rRNA降解,仅在这些病例中对TRAP分析进行了解读。正常组织均未表现出端粒酶活性。相比之下,所有25例癌症和47%(14/30)的腺瘤呈阳性。在腺瘤中,端粒酶激活与发育异常程度高度显著相关(p<0.0001)。所有含有高级别发育异常的腺瘤均显示端粒酶活性,而仅20%(4/20)的仅为低级别发育异常的病例可检测到端粒酶活性。这些结果表明,端粒酶激活可能是结直肠癌发生中的一个必要步骤,发生在腺瘤从低级别到高级别发育异常的进展过程中。此外,在腺瘤-癌序列中,端粒酶激活似乎比K-ras突变发生得晚,但比p53突变发生得早。